NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03933735: Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE